A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

被引：14

作者：

Sekeres, Mikkael A. ^{[1
]}

Schuster, Michael W. ^{[2
]}

Joris, Magalie ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Kovacsovics, Tibor ^{[7
]}

Verma, Amit ^{[8
]}

Vyas, Paresh ^{[9
]}

Wang, Eunice S. ^{[10
]}

Ma, Weidong Wendy ^{[11
]}

Zeremski, Mirjana ^{[11
]}

Kudla, Arthur ^{[11
]}

Chan, Geoffrey ^{[11
]}

Zeidan, Amer M. ^{[12
,13
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] SUNY Stony Brook, Hosp Canc Ctr, Stony Brook, NY USA

[3] CHU Amiens Picardie, Amiens, France

[4] Med Klin Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Hematol & Oncol, Bronx, NY 10467 USA

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Pfizer Oncol, New York, NY USA

[12] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA

[13] Yale Univ, Yale Canc Ctr, New Haven, CT USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124050

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

177

引用

页数：6

共 50 条

[21] Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation
Cabrera, Cristina Calderon
Falantes, Jose F.
Gomez, Marina
Parody, Rocio
Malaver, Francisco J. Marquez
Martino, Marla L.
Gonzalez, Jose
Montero, Isabel
Espigado, Ildefonso
Perez-Simon, Jose Antonio
BLOOD, 2013, 122 (21)
[22] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
Seymour, John F.
Silverman, Lewis R.
Doehner, Hartmut
Fenaux, Pierre
Mufti, Ghulam J.
Santini, Valeria
Minden, Mark D.
Stone, Richard M.
Lucy, Lela M.
Songer, Stephen
Dougherty, Donna
Hinkle, Randy
Gambini, Dominique
Beach, C. L.
Dombret, Herve
BLOOD, 2015, 126 (23)
[23] Phase 1 study of LP-108 as monotherapy and in combination with azacitidine in patients with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).
Walker, Alison R.
Bergua Burgues, Juan Miguel
Montesinos, Pau
Bixby, Dale
Guastad Daver, Naval
Konopleva, Marina
Patrick Anthony, Stephen
Tan, Fenlai
Chen, Yi
Chen, Yu
Shen, Yue
William Burke, Patrick
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
Madry, Krzysztof
Lis, Karol
Biecek, Przemyslaw
Mlynarczyk, Magda
Rytel, Agoda
Gorka, Michal
KacFrzyk, Piotr
Dutka, Magdalena
Rodzaj, Marek
Bolkun, Lukasz
Krochmalczyk, Dorota
Latka, Ewa
Drozd-Sokolowska, Joanna
Waszczuk-Gajda, Anna
Knopinska-Posluszny, Wanda
Kopinska, Anna
Subocz, Edyta
Masternak, Anna
Guzicka-Kazimierczak, Renata
Gil, Lidia
Machowicz, Rafal
Bilinski, Jaroslaw
Giebe, Sebastian
Czerw, Tomasz
Dwilewicz-Trojaczek, Jadwiga
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 264 - +
[25] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
Sekeres, Mikkael A.
Tiu, Ramon V.
Komrokji, Rami
Lancet, Jeffrey
Advani, Anjali S.
Afable, Manuel
Englehaupt, Ricki
Juersivich, Joyce
Cuthbertson, David
Paleveda, Jennifer
Tabarroki, Ali
Visconte, Valeria
Makishima, Hideki
Jerez, Andres
Paquette, Ronald
List, Alan F.
Maciejewski, Jaroslaw P.
BLOOD, 2012, 120 (25) : 4945 - 4951
[26] Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes
Kota, Vamsi
Ogbonnaya, Augustina
Farrelly, Eileen
Schroader, Bridgette Kanz
Raju, Aditya
Kristo, Fjoralba
Dalal, Mehul
FUTURE ONCOLOGY, 2022, 18 (36) : 4017 - 4029
[27] Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
Voso, Maria Teresa
Breccia, Massimo
Lunghi, Monia
Poloni, Antonella
Niscola, Pasquale
Finelli, Carlo
Bari, Alessia
Musto, Pellegrino
Zambello, Renato
Fianchi, Luana
Alimena, Giuliana
Leone, Giuseppe
EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (04) : 345 - 348
[28] Randomized Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk Myelodysplastic Syndromes/Chronic Myelomonocytic Leukemia or Low-Blast Acute Myeloid Leukemia: Exploratory Analysis of Patient-Reported Outcomes
Zeidner, Joshua F.
Mazerolle, Flora
Bell, Jill A.
Cain, Lauren E.
Faller, Douglas V.
Dalal, Mehul
Regnault, Antoine
Fram, Robert J.
BLOOD, 2020, 136
[29] 5-Azacitidine Therapy in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia: a Single Institution Experience
Freyrie, Alessandra
Reda, Gianluigi
Vincenti, Daniele
Sciume, Mariarita
Binda, Francesca
Guidotti, Francesca
Cortelezzi, Agostino
BLOOD, 2012, 120 (21)
[30] Phase 1b/2 Combination Study of APR-246 and Azacitidine in Patients With TP53-Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)

← 1 2 3 4 5 →